Rob Neville (L) and Taneli Jouhikainen
September 11, 2020 11:01 AM EDT
People

Savara's long-reign­ing duo both re­sign in the wake of CF bust

Amber Tong

As Savara’s cys­tic fi­bro­sis de­vel­op­ment pro­gram comes to an end, so will the CEO Rob Neville’s 12-year reign at the com­pa­ny.

Fol­low­ing him out the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times